GenoScreen and ScienceVision announce an agreement to commercialize the Deeplex® Myc-TB test in Malaysia, Myanmar and Brunei.

Following the Government's announcements concerning the COVID-19 pandemic, we are pleased to inform you that we have taken the necessary measures to ensure that all of our activities are maintained while guaranteeing the safety for our employees.

Tuberculosis has been a major scourge since antiquity. The fight against this disease requires ever more efficient technologies. GenoScreen, a French biotech company, has recently developed a new weapon for predicting antibiotic resistance in the germs responsible for this disease. This new test, which comes in the form of a kit, quickly and efficiently detects the genetic mutations in the DNA of pathogenic germs and guides doctors in their medical prescriptions. This test is already being implemented in some thirty countries.

Press release - The innovative Deeplex® Myc-TB antibiotic resistance prediction test has been evaluated by an international research team. By analyzing data from more than 5,600 strains and samples of various origins and types, this study measures for the first time the sensitivity, specificity and detection limit of this test.

Press release - Researchers from GenoScreen and the Cardio-Thoracic Research Centre of Bordeaux (Inserm U1045) have demonstrated relationships between microorganisms in indoor air and those in asthmatic patients’ lungs. This work, published in the Journal of Allergy and Clinical Immunology and highlighted by the American Academy of Allergy, Asthma and Immunology (AAAI), also shows a variation in these micro- and mycobiota according to the patients’ inflammatory reaction type (T2 endotype).

GenoScreen is sponsor of the Genetics and Genomics Symposium organized by Equipex LIGAN-PM, entitled "The Magnificent Last Decade In Genetics and Genomics".

This symposium will take place on March 13, 2020 at the Faculty of Medicine of the University of Lille.

Program of the event :

Register by clicking here

This is confirmed by preliminary results of the PEOPLE study. This study is an opportunity for GenoScreen to apply its "Deeplex® Myc-Lep" sequencing assay for the first time to an international study.

Louise-Eva VANDENBORGHT supported her thesis for the degree of doctor of the University of Bordeaux

By continuing your visit to this site, you accept the use of statistics cookies